98%
921
2 minutes
20
Background: Accurate formulation of an intravenous infusion is critical in ensuring its smooth implementation. However, in clinical practice, owing to the diverse reasons for drug preparation, some patients cannot obtain safe and accurate medications, especially in pediatric infusion rooms. Pediatric patients often experience adverse reactions as the dosage administered does not meet the requirements or exceeds the recommended dose.
Methods: Finished product infusion of potassium sodium dehydroandrographolide succinate (PSDS) was used as the study drug. Drug residue samples from the finished product infusion bags were collected randomly in the pediatric infusion room and clinical wards before (from October 2022 to December 2022) and after (from May 2023 to July 2023) the plan-do-check-action (PDCA) cycle intervention. High-performance liquid chromatography (HPLC) was used to determine the drug content. Comparisons of the changes in the proportion of the drug in the infusion were made based on the monitoring results.
Results: After PDCA cycle intervention, the qualified rates of whole, non-whole, and overall infusions increased from 92.95%, 82.68%, and 86.59% to 97.56%, 95.12%, and 96.10% (P < 0.05), respectively. The accuracy and uniformity of the infusion preparations significantly improved.
Conclusions: The combination of HPLC and PDCA cycle management can effectively improve the quality of pediatric infusion preparations and enhance their effectiveness.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12166566 | PMC |
http://dx.doi.org/10.1186/s40780-025-00457-y | DOI Listing |
J Pediatr Hematol Oncol
September 2025
Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Medical College of Wisconsin.
Background: While pegylated Escherichia coli asparaginase (PEG) is an integral component of leukemia and lymphoma treatment, hypersensitivity reactions (HSR) remain a common adverse event, often resulting in adjustments to the treatment regimen, increasing the burden on patients and families. HSR to asparaginase often indicates a transition to Erwinia asparaginase (ERW), which requires patients to return to the hospital 6 times for subcutaneous injections to replace one dose of IV PEG. Previous trials have demonstrated rates of HSR to pegylated E.
View Article and Find Full Text PDFDrug Des Devel Ther
September 2025
Department of Anesthesiology, The Affiliated Women and Children's Hospital of Ningbo University, Ningbo, Zhejiang, People's Republic of China.
Background: Emergence delirium (ED) is a common postoperative complication during the recovery period in pediatric anesthesia. Continuous intravenous infusion of remimazolam can effectively prevent the occurrence of ED. However, the optimal dose for preventing ED in pediatric patients remains unclear.
View Article and Find Full Text PDFBr J Haematol
September 2025
Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
In allogeneic haematopoietic stem cell transplantation (HSCT), important clinical decisions depend upon assessment of chimerism, including immunosuppressant dosing and donor lymphocyte infusions (DLI), which in turn can have major impacts on disease control, graft-versus-host disease (GVHD), immunity and ultimately patient survival. There is a complex range of clinical and laboratory procedural considerations including methodology of testing, types of cell subset selection, frequency of testing, urgency of turnaround times (TATs), interplay with measurable residual disease (MRD) monitoring and duration of testing post-transplant. These aspects are routinely adapted according to disease indication, patient characteristics, donor source and intensity of transplant technique.
View Article and Find Full Text PDFDig Liver Dis
September 2025
Division of Pediatric Gastroenterology and Nutrition, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel-Hashomer, Israel; The Gray Faculty of Medical and Health Sciences, Tel-Aviv University, Tel-Aviv, Israel; Cincinnati Children's Hospital Medical Center and the University of Cin
Background And Aims: The development of antibodies to infliximab (ATI) is a major challenge in pediatric inflammatory bowel disease (IBD). This real-world study aimed to identify predictors of ATI, evaluate strategies to overcome ATI, and compare the durability of continuing infliximab (IFX) versus switching to adalimumab (ADA) after ATI development.
Methods: We retrospectively analyzed 194 pediatric IBD patients treated with IFX from 2010 to 2024.
Cureus
August 2025
Anesthesiology, Om Prakash (OP) Jindal Institute of Medical Sciences, Hisar, IND.
Congenital diaphragmatic hernia (CDH) is a serious congenital anomaly often associated with pulmonary hypoplasia and persistent pulmonary hypertension of the newborn (PPHN). Central vascular access such as umbilical arterial catheters (UACs) is routinely used in neonatal intensive care but is associated with the risk of vascular complications, including thromboembolic events. We present a case of preterm dichorionic diamniotic (DCDA) twins born at 34 weeks of gestation with antenatally diagnosed CDH.
View Article and Find Full Text PDF